Navigation Links
ImpactRx Measures How Patient Brand Requests Drive Physician Treatment Decisions
Date:7/6/2011

MOUNT LAUREL, N.J., July 6, 2011 /PRNewswire/ -- ImpactRx, the pioneer in measuring the impact of promotion on physician prescribing behavior, offers pharmaceutical brand managers unique insight into the effectiveness of their direct-to-consumer promotional efforts.  ImpactRx's proprietary database, ImpactData™, annually captures more than 250,000 brand requests by patients.   ImpactRx then records physicians' treatment behavior in response to these requests from their patients.

ImpactRx's longitudinal research model provides information on changes in patient request trends over time.  Through the ImpactData, the effectiveness of a brand's DTC campaign can be quickly measured by the change in share of patient requests generated before and after the campaign's initiation.

Additionally, ImpactRx uniquely tracks how often physicians honor requests from their patients across all therapeutic areas.  The ImpactData documents that patient requests underlie a greater proportion of physician usage of lifestyle drugs for the treatment of conditions such as erectile dysfunction and smoking cessation than usage of medications for chronic conditions like high cholesterol or diabetes.  More than 20% of lifestyle treatments are associated with a patient request, while less than 5% of chronic medications have a corresponding request.  Physician fulfillment rates per patient request, however, are similar for most therapeutic areas.  Adding sample usage by physicians to their prescription writing increases the overall average fulfillment rate per request to about 85%.

Lesley Bailey, Senior Director, Product Development/Marketing at ImpactRx, stated, "although there are differences in degree across markets, our data clearly shows that patient requests influence physician behavior.  The longitudinal nature of our research model coupled with its physician-level linkage from request through to fulfillment, enables us to provide our clients unique insight into the effectiveness of their DTC campaigns," Bailey continued.  "To get a true read on the impact of their DTC efforts, our clients need to know not only if they are generating requests for their brands, but also if physicians are honoring those requests," said Bailey.

"The effectiveness of Uloric's recent DTC activity in the gout market is something we're watching closely," stated Bailey.  "Patients are requesting Uloric at higher-than-average rates, so the ultimate success of the brand's campaign will hinge on its ability to educate physicians to fulfill those requests," Bailey finished.

ImpactRx's panels span fourteen specialties including Primary Care, Oncology, Endocrinology, Cardiology, Rheumatology and Neurology.  New panels supporting Pulmonology and Adult Psychiatry were launched earlier this year.

About ImpactRx

Founded in 2000 and headquartered in Mount Laurel, N.J., ImpactRx's longitudinal panels of high value, iPhone-connected physicians are the exclusive source of continuously-captured promotion and treatment data. Through its proprietary methodology, the Company annually captures one million details and three-million treatment decisions, fueling its unique ImpactData™ industry database. ImpactRx is a private company with investment financing provided by Symphony Technology Group (www.symphonytg.com) and Merck Capital Ventures.  For more information, visit: www.impactrx.com.

CONTACT:  
Lesley Bailey
Senior Director, Product Development/Marketing
ImpactRx, Inc.
856-802-4133
lbailey@impactrx.com


'/>"/>
SOURCE ImpactRx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
2. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
3. ImpactRx Releases 2010 Oncology Promotion Report
4. ImpactRx Acquired by Symphony Technology Group
5. ImpactRx Expands Psychiatry Research Panel to Include Adolescent Psychiatrists
6. ImpactRx Names Kjell Nygren Vice President, Analytical Services
7. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
8. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
9. ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services
10. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
11. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017   Spotlight Innovation ... Caretta Therapeutics plans, in the second quarter of ... topical roll-on intended to provide relief from chronic ... steroidal analgesics. It was developed under a licensing ... commercialize products derived from snake venom. Additionally, Caretta ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
(Date:1/18/2017)... from 6% to 10%, South East Asia,s pharma industry is ... the industry by fostering the regional discourse - Sign up today ! ... ASEAN -- India strategic sourcing Forum ... business matchmaking program Roadshows ... ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... A Palm Beach doctor plans to run the ... charity that provides free surgery to poor children suffering from cleft lip and cleft ... have run to support the efforts of the American Heart Association and the Leukemia ...
(Date:1/18/2017)... Spring, MD (PRWEB) , ... January 18, 2017 , ... ... financial consultations to families and business owners in central Maryland and the DC region, ... , Heart disease kills 787,000 people nationally every year, making it the #1 killer ...
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment to quality ... achieved certification to ISO 13485. This certification is another way they are making constant ... and services that they need. , The ISO 13485 Certification is a major accomplishment ...
(Date:1/18/2017)... ... January 18, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that Mr. Michael Merges, Director of ... Conference, to be held at the Mayflower Hotel, Washington DC, on Jan. 24 ...
(Date:1/18/2017)... ... January 18, 2017 , ... The ... an aid project with the donation of cochlear implants. In February 2017, the ... and thus a fair chance of leading an independent life. This engagement builds ...
Breaking Medicine News(10 mins):